Sakarie Mustafe Hidig | Cancer Cell Biology | Research Excellence Award

Dr. Sakarie Mustafe Hidig | Cancer Cell Biology | Research Excellence Award

Zhejiang University School of Medicine | United Kingdom

Dr. Sakarie Mustafe Hidig is a General Surgeon, Clinical Researcher, and Editor-in-Chief affiliated with Zhejiang University School of Medicine and the Research Center at Hargeisa Group Hospital. He serves as the UK Country Coordinator for the International Institute of Knowledge Management (TIIKM) and is an active member of the China Medical Association, Somali Medical Association, and the Scholars Academic and Scientific Society. Dr. Hidig has earned multiple international honors, including the SHEN Best Researcher Awards, GCDMSE-2024, and ISSN Research Awards. With over 70 published papers, 280+ SCI editorial handling experiences, and 14 research projects, his work spans general, gastrointestinal, trauma, emergency, hepatobiliary, and pancreatic surgery. He also contributes as an editor for major journals such as PLOS One Medicine, Annals of Medicine and Surgery, Obesity Surgery, and JMIR Public Health and Surveillance. His research interests include surgical oncology, hepatology, pancreatic cancer, and public health.

Citation Metrics (Scopus)

40

30

20

10

0

Citations
12

Documents
7

h-index
2

Citations
Documents
h-index



View Scopus Profile

Featured Publication

Hongjin Liu | Cancer Cell Biology | Research Excellence Award

Dr. Hongjin Liu | Cancer Cell Biology | Research Excellence Award

National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital & Shenzhen Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College | China

Hongjin Liu is a medical oncologist whose research centers on cancer biology, therapeutic resistance, and tumorigenesis. His work spans molecular oncology, hepatocellular carcinoma, and mechanisms of somatic mutagenesis across human tissues. He has contributed to high-impact studies published in Nature and Signal Transduction and Targeted Therapy, including investigations uncovering the landscape of somatic mutations in normal tissues and the critical role of VAV2 in DNA repair and radiotherapy resistance. His research also explores noncoding RNAโ€“mediated regulatory networks in liver cancer, notably identifying the oncogenic function of ELF3-AS1 through its modulation of the miR-98-5p/CPSF4 axis. Collectively, his publications provide important insights into genomic instability, tumor microenvironment dynamics, and potential molecular targets for improving therapeutic outcomes. His translational research aims to bridge molecular mechanisms with clinical oncology to support precision cancer treatment and advance strategies for overcoming therapy resistance.

Profile: Orcid

Featured Publications:ย 

1. Ge, P., Niu, S., Fang, M., Xu, Q., Zhang, W., Xu, J., Yang, F., Wang, Y., Shi, T., & Liu, H. (2025). ELF3-AS1 promotes the carcinogenesis of hepatocellular carcinoma cells by inhibiting miR-98-5p/CPSF4 axis. Nucleosides, Nucleotides & Nucleic Acids.

2. Zhang, W., Liu, Z., Liu, H., Huang, Z., Huang, X., Xu, L., Che, X., & Zhan, Z. (2025). The impact of immune checkpoint inhibitors on prognosis in unresectable hepatocellular carcinoma treated with TACE and lenvatinib: A meta-analysis. Frontiers in Immunology.

3. Liu, W., Miao, C., Zhang, S., Liu, Y., Niu, X., Xi, Y., Guo, W., Chu, J., Lin, A., Liu, H., Yang, X., Chen, X., Zhong, C., Ma, Y., Wang, Y., Zhu, S., Liu, S., Tan, W., Lin, D., & Wu, C. (2021). VAV2 is required for DNA repair and implicated in cancer radiotherapy resistance. Signal Transduction and Targeted Therapy, 6(9), 2906โ€“2919.

4. Li, R., Di, L., Li, J., Fan, W., Liu, Y., Guo, W., Liu, W., Liu, L., Li, Q., Chen, L., Chen, Y., Miao, C., Liu, H., Wang, Y., Ma, Y., Xu, D., Lin, D., Huang, Y., Wang, J., Bai, F., & Wu, C. (2021). A body map of somatic mutagenesis in morphologically normal human tissues. Nature, 597(7876), 398โ€“403.

5. Chen, Y., Zeng, Q., Liu, X., Fu, J., Zeng, Z., Zhao, Z., Liu, Z., Bai, W., Dong, Z., & Liu, H. (2018). LINE-1 ORF-1p enhances the transcription factor activity of pregnenolone X receptor and promotes sorafenib resistance in hepatocellular carcinoma cells. Cancer Management and Research, 10, 6345โ€“6358.

Varsha Rathore | Cancer Biology | Best Researcher Award

Dr. Varsha Rathore | Cancer Biology | Best Researcher Award

Department of Pharmacology, College of Medicine, National Taiwan University, Taipei 100233 | Taiwan

Dr. Varsha Rathoreโ€™s research focuses on elucidating the molecular mechanisms underlying cancer cell migration, invasion, and survival, with a particular emphasis on the role of CASK (Calcium/Calmodulin-dependent Serine Protein Kinase) in prostate cancer progression. Her doctoral work explores how CASK promotes tumor cell motility and invasiveness independent of TGF-ฮฒ signaling, contributing to a deeper understanding of tumor metastasis. Additionally, she investigates the involvement of NLRX1 in regulating proliferation, invasion, and survival pathways in prostate cancer cells, offering insights into novel therapeutic targets for cancer treatment. Her expertise spans cell culture, molecular biology, and biochemical assays, including protein expression, purification, ubiquitination, kinase, and PARylation assays, as well as metabolic analysis using Seahorse technology. She has presented her findings at international conferences, including the 19th World Congress of Basic and Clinical Pharmacology and the 38th Joint Academic Conference on Biomedicine. Through her research, Dr. Rathore contributes significantly to the field of molecular oncology and pharmacology, advancing knowledge on how signaling proteins orchestrate cancer progression and identifying potential molecular targets for therapeutic intervention.

Profile: Orcid

Featured Publications:

Rathore, V., Cheng, C.-Y., Lin, C.-Y., Chang, C.-R., & Lin, W.-W. (2025). CASK promotes prostate cancer progression via kinase-dependent activation of AKT. International Journal of Biological Macromolecules, 311(Pt 2), 143965.

Rathore, V., & Lin, W.-W. (2025). Decoding SIGLEC12 in bladder cancer: In silico profiling of expression, tumorโ€“immune interactions, and prognostic impact. Medicina, 61(11), 1894.

Mishra, M., Rathore, V., Sahu, S., & Sahoo, H. (2019). The contribution of nanostructures towards the wing patterning of yellow Catopsilia pomona: How it differs from the lime. Microscopy, 68(4), 289โ€“300.

Shaoqing Ai | Cancer | Best Researcher Award

Mr. Shaoqing Ai | Cancer | Best Researcher Award

Xiโ€™an Daxing Hospital | China

Dr. Shaoqing Aiโ€™s research focuses on the clinical application and translational potential of integrated traditional Chinese and Western medicine in oncology, particularly in the management of gastrointestinal tumors, lung cancer, and gynecological malignancies. His work emphasizes optimizing multidisciplinary treatment strategies and improving patient outcomes through precision diagnosis and therapy. As an active contributor to the fields of tumor metastasis and geriatric oncology, he has participated in a research project exploring the molecular mechanisms and clinical management of tumor progression and treatment-related complications. His published studies, including one SCI-indexed paper and two Chinese core journal articles, highlight the therapeutic efficacy of combined treatment approaches in reducing radiotherapy- and chemotherapy-induced hematologic toxicities such as leukopenia and thrombocytopenia. Dr. Aiโ€™s research also aims to refine clinical protocols for mitigating adverse effects while enhancing the overall quality of life for cancer patients. Through his involvement in professional oncology committees and collaborative studies, he continues to advance the integration of evidence-based Chinese medicine with modern oncological practices, contributing to the growing body of knowledge supporting individualized and holistic cancer care.

Profile: Orcid

Featured Publications:

Ai, S., Jun, G., Jia, W., & Jie, L. (2025, October 16). Correlation analysis between frequency of gastrointestinal bleeding episodes and abnormal coagulation indexes in digestive system tumors. Scientific Reports. https://doi.org/10.1038/s41598-025-19012-8

 

 

Waldemar Debinski | Cancer Cell Biology | Best Researcher Award

Prof. Dr. Waldemar Debinski | Cancer Cell Biology | Best Researcher Award

Wake Forest School of Medicine | United States

Dr. Waldemar Debinski, M.D., Ph.D., is a distinguished neuroscientist and cancer researcher recognized for his pioneering work in brain tumor biology and targeted molecular therapies. His research focuses on understanding the molecular mechanisms that drive the development and progression of malignant brain tumors, with a particular emphasis on gliomas. Dr. Debinski has significantly contributed to the development of novel targeted therapeutics, including receptor-directed cytotoxins and biologics designed to selectively eliminate tumor cells while sparing healthy tissues. His investigations bridge molecular oncology, translational science, and clinical application, aiming to improve therapeutic outcomes for patients with brain cancers. Throughout his career, he has integrated insights from physiology, molecular biology, and pharmacology to develop translational approaches that move from laboratory discovery to clinical implementation. His extensive research has advanced the understanding of tumor-specific receptors and intracellular signaling pathways, contributing to innovative strategies in cancer immunotherapy and precision medicine. Dr. Debinskiโ€™s work exemplifies the integration of basic and clinical research toward the development of next-generation treatments for central nervous system malignancies, positioning him as a leading figure in neuro-oncology and translational cancer research.

Profile: Scopus

Featured Publications:

Wocial, B., Januszewicz, W., Siedlecki, J., Feltynowski, T., & Debinski, W. (1982). Alterations in plasma dopamine-ฮฒ-hydroxylase and catecholamine concentrations during surgical removal of pheochromocytoma. Endocrinologie, 79, 131โ€“139.

Debinski, W., & Wocial, B. (1982). Various aspects of sodium metabolism in hypertension [in Polish]. Polski Tygodnik Lekarski, 37, 1339โ€“1342.

Ignatowska-ลšwitalska, H., Debinski, W., & Chojnowski, K. (1983). The role of certain hormonal factors in arterial hypertension [in Polish]. Materia Medica Polona, 15, 74โ€“86.

Wasawska, T., Feltynowski, T., Majewska, Z., Januszewicz, W., Sobolewska-Karwowska, A., Wocial, B., & Debinski, W. (1984). Pheochromocytoma: Description of two cases with an unusual clinical picture [in Polish]. Polski Tygodnik Lekarski, 39, 261โ€“263.

Czarkowski, M., & Debinski, W. (1984). Sodium and primary arterial hypertension [in Polish] (Review). Kardiologia Polska, 27, 967โ€“976.

Wocial, B., Debinski, W., Jablonska-Skwicinska, E., Feltynowski, T., Chodakowska, J., Kozakowska, E., & Januszewicz, W. (1984). Sodium content of erythrocytes in patients with arterial hypertension [in Polish]. Polski Archiwum Medycyny Wewnetrznej, 72, 167โ€“174.

Garcia, R., Debinski, W., Gutkowska, J., Kuchel, O., Thibault, G., Genest, J., & Cantin, M. (1985). Gluco- and mineralocorticoids may regulate the natriuretic effect and the synthesis and release of atrial natriuretic factor by the rat atria in vivo. Biochemical and Biophysical Research Communications, 131, 806โ€“814.

Debinski, W., Kuchel, O., Garcia, R., Buu, N. T., Racz, K., Cantin, M., & Genest, J. (1986). Atrial natriuretic factor inhibits sympathetic activity in one-kidney, one-clip hypertension in the rat. Proceedings of the Society for Experimental Biology and Medicine, 181, 173โ€“177.

Debinski, W., Kuchel, O., Buu, N. T., Garcia, R., Cantin, M., & Genest, J. (1986). Involvement of the adrenal glands in the action of the atrial natriuretic factor. Proceedings of the Society for Experimental Biology and Medicine, 181, 318โ€“324.

Debinski, W., Gutkowska, J., Kuchel, O., Racz, K., Buu, N. T., Cantin, M., & Genest, J. (1986). ANF-like peptide(s) in the peripheral autonomic nervous system. Biochemical and Biophysical Research Communications, 134, 279โ€“284.

Alexander Tsankov | Cancer Cell Biology | Best Researcher Award

Assoc. Prof. Dr. Alexander Tsankov | Cancer Cell Biology | Best Researcher Award

Icahn School Of Medicine At Mount Sinai | United States

Alexander Tsankov is a leading researcher in computational biology and cancer genomics, known for his contributions to single-cell and spatial transcriptomics. He holds dual bachelor’s degrees in Plan II Honors and Electrical and Computer Engineering from the University of Texas at Austin, and earned his M.S. and Ph.D. in Electrical Engineering and Computer Science from MIT. His research focuses on understanding the cellular and molecular mechanisms underlying cancer progression and tissue remodeling, with an emphasis on glioblastoma, lung adenocarcinoma, and colorectal cancer. Dr. Tsankov has published extensively in top-tier journals such as Nature, Nature Communications, Cancer Discovery, Nature Genetics, and Immunity. He has authored over 50 peer-reviewed publications, with an h-index of 36 and more than 15,000 citations according to Google Scholar. His work has earned him several prestigious honors, including the NIH NRSA postdoctoral fellowship and the NSF graduate fellowship. Dr. Tsankov frequently serves as a senior or corresponding author, highlighting his leadership in the field of computational oncology and single-cell genomics.

Profile: Google Scholar

Featured Publications:

  • “Learning the cellular origins across cancers using single-cell chromatin landscapes”

  • “Cellular and spatial atlas of TP53-associated tissue remodeling defines a multicellular tumor ecosystem in lung adenocarcinoma”

  • “Single cell profiling of human airway identifies tuft-ionocyte progenitor cells displaying cytokine-dependent differentiation bias in vitro”

  • “Single-cell dissection of the genotype-immunophenotype relationship in glioblastoma”

  • “Glioblastoma shift from bulk to infiltrative growth is guided by plexin-B2-mediated microglia alignment in invasive niches”

  • “Oncofetal reprogramming drives phenotypic plasticity in WNT-dependent colorectal cancer”

  • “NOTCH1 drives sexually dimorphic immune responses in hepatocellular carcinoma”

  • “Microglia and monocyte-derived macrophages drive progression of pediatric high-grade gliomas and are transcriptionally shaped by histone mutations”

  • “Single cell view of tumor microenvironment gradients in pleural mesothelioma”

  • “Hypoxia drives shared and distinct transcriptomic changes in two invasive glioma stem cell lines”

Dukagjin Blakaj | Radiation Oncology | Best Researcher Award

Prof. Dukagjin Blakaj | Radiation Oncology | Best Researcher Award

Prof. Dukagjin Blakaj, The Ohio State University, United States

Dr. Dukagjin M. Blakaj, MD, PhD, is a distinguished physician-scientist and academic leader in radiation oncology, specializing in proton therapy. Currently serving as the Vice Chair of Clinical Operations and holding the prestigious Drs. Malati and Ganesh Potdar Endowed Professorship at The Ohio State University Comprehensive Cancer Center โ€“ James Cancer Hospital, he brings visionary leadership in patient-centered oncology care. With dual degrees in medicine and biochemistry, Dr. Blakaj integrates clinical expertise with advanced translational research. He is renowned for developing innovative radiotherapy protocols, advancing artificial intelligence applications in oncology, and mentoring future clinician-scientists. His work significantly influences treatment outcomes for head and neck cancers, including HPV-related oropharyngeal cancer, and is published in top-tier journals. A respected thought leader and collaborative partner, Dr. Blakaj embodies excellence in academic medicine, multidisciplinary team leadership, and compassionate patient care.

Publication Profile:ย 

Google Scholar

Scopus

Orcid

Education:

Dr. Blakajโ€™s educational path is both extensive and interdisciplinary. He earned his MD, PhD, and MS in Biochemistry from the Albert Einstein College of Medicine in New York, where he focused on molecular interactions in biological systems. Before that, he completed both a BA in Chemistry and Molecular Biology & Biophysics and an MA in Chemistry from Wesleyan University in Middletown, CT. His doctoral work explored protein-RNA interactions, laying the groundwork for his scientific rigor and precision. This strong biochemical foundation supports his innovative clinical research in radiation oncology and immunotherapy. His education highlights a consistent pattern of academic excellence and intellectual curiosity, equipping him with a rare blend of clinical insight and research acumen that continues to impact cancer treatment paradigms worldwide.

Professional Experience:

Dr. Dukagjin Blakaj is the Vice Chair of Clinical Operations in Radiation Oncology and Drs. Malati and Ganesh Potdar Endowed Professor in Proton Therapy at OSUCCC โ€“ James Cancer Hospital. As a senior faculty member, he has led transformative improvements in clinical care, quality assurance, and translational oncology research. His multidisciplinary collaboration extends across surgery, radiology, oncology, and data science, driving innovations such as AI-guided treatment protocols and digital health integration. Dr. Blakaj has also played a critical role in operationalizing proton therapy and implementing personalized cancer therapies. His background spans high-impact clinical trials, program development, and mentorship. The combination of clinical leadership and academic scholarship positions him as a strategic thinker with practical, evidence-driven execution. His commitment to precision medicine and patient-centered care distinguishes him among modern radiation oncologists.

Awards and Honors:

Dr. Blakaj has received numerous accolades that reflect his clinical excellence, research innovation, and service to the academic community. Notably, he was awarded the Drs. Malati and Ganesh Potdar Endowed Professorship in Radiation Oncology โ€“ Proton Therapy (effective June 2025), the highest honor granted by Ohio State University. His ABR Volunteer Service Award (July 2025) highlights his contributions to professional standards and education. He was selected for the James Outstanding Physician Peer Award for exemplary leadership, professionalism, and collaboration (August 2024). Additionally, his abstract ranked in the Top 7 of 146 presentations at ACRO, underscoring his researchโ€™s national impact. Dr. Blakajโ€™s consistent recognition across service, research, and teaching is a testament to his dedication, integrity, and influence in the field of oncology.

Research Focus:

Dr. Blakajโ€™s research is centered on optimizing cancer treatment outcomes through precision radiation therapy, immunotherapy integration, and the application of artificial intelligence in oncology. He focuses primarily on head and neck cancers, with additional emphasis on HPV-associated oropharyngeal carcinoma, FLASH radiotherapy, and treatment response prediction using circulating tumor DNA and inflammatory indices. He co-leads interdisciplinary studies leveraging machine learning, big data, and digital health tools to personalize care and reduce treatment toxicity. His research is both translational and clinically grounded, often influencing national clinical practice guidelines and multi-center trials. As a key contributor to high-impact publications, Dr. Blakaj has established himself as a thought leader in adaptive radiotherapy and survivorship outcomes. His pioneering work in proton therapy protocols and patient-reported outcomes continues to bridge the gap between innovative science and practical oncology care.

Publications Top Notes:ย 

  1. An integrated ML-based prognostic model in head and neck cancer using inflammatory markers and financial toxicity

  2. Vertebral endplate disruption and compression fracture risk: Expanded radiotherapy analysis

  3. Nasopharyngeal carcinoma in nonendemic regions: Characteristics and treatment outcomes

  4. Emerging paradigms in radiation oncology: Evolution and patient-centric care

  5. FLASH radiotherapy: From in vivo data to clinical translation

  6. Digital health tools in radiation oncology: Development and implementation review

  7. ctDNA as a response marker in HPV-associated oropharyngeal carcinoma: A pilot study

  8. AI, machine learning, and big data in radiation oncology

  9. Predicting cisplatin tolerability in elderly head and neck cancer patients

  10. ย Tobacco, marijuana, and alcohol use impact on survival in metastatic head and neck cancer

Conclusion:

Dr. Dukagjin M. Blakaj is a highly qualified, forward-thinking researcher whose body of work exemplifies excellence in translational oncology. He brings together advanced clinical practice, cutting-edge research, and visionary leadership to improve cancer care outcomes and drive future innovations in radiation therapy.

Given his sustained productivity, multidisciplinary leadership, and contributions to patient-centered care models, Dr. Blakaj is a deserving and outstanding nominee for the Best Researcher Award.

Amr Hanbali | Therapeutic use of Cellular therapy in cancer treatment | Best Researcher Award

Assoc. Prof. Dr. Amr Hanbali | Therapeutic use of Cellular therapy in cancer treatment | Best Researcher Award

Assoc. Prof. Dr. Amr Hanbali | King Faisal Specialist Hospital & Research Center | Saudi Arabia

Dr. Amr AlHanbali is a dual-certified Hematology and Oncology consultant with over 18 years of experience in malignant and benign hematological conditions. Based at King Faisal Specialist Hospital & Research Center in Riyadh, Saudi Arabia, he specializes in hematologic malignancies and stem cell transplantation. Dr. AlHanbali previously served as a senior staff physician and Associate Fellowship Program Director at Henry Ford Health System in Detroit, Michigan. Recognized for his academic involvement, he holds teaching appointments at Wayne State University and Alfaisal University. Known for his dedication to clinical mentorship, he has trained numerous medical students, residents, and fellows. He is actively involved in research and is a member of several prestigious medical organizations including the American Society of Hematology and American Society of Clinical Oncology. With expertise ranging from bone marrow procedures to managing complex hematologic disorders, Dr. AlHanbali is a respected leader in the field of hematology and stem cell transplantation.

Publication Profile:

Scopus

Strengths for the Award:

  1. Extensive Research Contribution

    • Over 17 peer-reviewed publications, including impactful case reports, national guidelines, and original research in hematology, oncology, and stem cell transplantation.

    • Active contributor to national guidelines on multiple myeloma, reflecting leadership in shaping national healthcare standards in KSA.

  2. Dual Academic and Clinical Roles

    • Combines academic excellence (as faculty at Wayne State University and Alfaisal University) with hands-on clinical expertise at a premier institution (King Faisal Specialist Hospital & Research Center).

  3. Innovative Focus in Hematology and Transplantation

    • Research into underexplored areas such as hepatitis B reactivation post-rituximab, genetic donor match outcomes, and therapies for AL amyloidosis.

  4. International Exposure and Leadership

    • Experience across the U.S. and Saudi Arabia, influencing programs in both systems.

    • Played a key role in training and selecting future hematology-oncology fellows in the U.S.

  5. Mentorship and Capacity Building

    • Mentored numerous trainees, enhancing research culture among younger clinicians.

Areas for Improvement:

  1. Higher Impact Publications Needed

    • While the volume and variety of research are commendable, more publications in top-tier journals (NEJM, Lancet, Blood, JCO) could boost citation impact and visibility.

  2. Research Grants and Collaborative Trials

    • Pursuing multicenter studies, international collaborations, or industry-sponsored clinical trials would further elevate his profile and expand research funding sources.

  3. Technological Innovation/Patents

    • Exploring biotech innovation, AI in diagnostics, or cellular therapy patents could position him among the top medical innovators.

Education:

Dr. Amr AlHanbali completed his Bachelor of Medicine and Surgery from the University of Jordan in 1999. He pursued medical training in the United States, starting with an internal medicine residency (2001โ€“2004) at Henry Ford Health System, Detroit. He continued his specialization with a fellowship in Hematology and Oncology (2004โ€“2007) at the same institution. During his training, he also undertook elective rotations in Pediatric Cardiology and Gastroenterology at the University of Texas Medical Branch, Galveston, further enriching his academic exposure. He is certified by the American Board of Internal Medicine in Internal Medicine (2004), Hematology (2007), and Oncology (2007). Dr. AlHanbali holds academic titles as a Clinical Assistant Professor at Wayne State University, Detroit, and Adjunct Associate Professor at Alfaisal University, Riyadh. His educational background reflects a strong foundation in internal medicine, with a deep focus on hematology and oncology, further supported by teaching and research excellence.

Experience:

Dr. AlHanbaliโ€™s clinical career spans over 18 years, currently serving as Hematology and Stem Cell Transplant Consultant at King Faisal Specialist Hospital & Research Center in Riyadh since 2013. Prior to this, he held multiple leadership roles at Henry Ford Health System, Detroit, including Senior Staff Physician and Associate Fellowship Program Director (2007โ€“2013). His medical expertise covers the diagnosis and treatment of a wide range of hematologic malignancies such as leukemia, lymphoma, multiple myeloma, and myeloproliferative disorders. Dr. AlHanbali also has extensive experience in stem cell transplantation, intrathecal chemotherapy, and bone marrow biopsy. He has been instrumental in resident selection and curriculum development for fellowship programs in hematology and oncology. His work bridges clinical excellence with academic mentorship, guiding numerous trainees and junior physicians. In addition to patient care, he is involved in clinical guideline development and research, particularly in the field of multiple myeloma and transplant outcomes.

Research Focus:

Dr. Amr AlHanbaliโ€™s research is centered on hematologic malignancies, particularly multiple myeloma, lymphoma, leukemia, and stem cell transplantation. His work explores novel therapeutic approaches, transplant outcomes, disease progression, and treatment-related complications. He has contributed significantly to research on hepatitis B reactivation, chemotherapy-induced toxicities, and the protective role of comorbidities like diabetes in cancer metastasis. As an active member of the Saudi Myeloma Working Group, he has co-authored national guidelines for both newly diagnosed and relapsed/refractory multiple myeloma. His studies also examine health disparities in cancer care, including outcomes among African American populations and the impact of familial genetics in donor matches. With over a dozen peer-reviewed publications and case reports in high-impact journals, Dr. AlHanbali continues to push forward understanding in clinical hematology and oncology. He combines bedside insights with academic rigor to shape evidence-based practice and improve treatment outcomes in cancer and transplant medicine.

Publications Top Notes:

  1. ย Mediastinal Hematoma With SVC Syndrome From A Central Venous Catheter Insertion โ€“ CHEST, 2003

  2. ย Diabetes Has Protective Effect Against Metastasis in Non-Small Cell Lung Cancer โ€“ Arch Intern Med, 2007

  3. ย Delayed Hepatitis B Viral Replication Post-Rituximab & Fludarabine in Waldenstrom Macroglobulinemia โ€“ Am J Hematol, 2007

  4. ย Acute Pancreatitis Induced by Adult Precursor B-cell ALL โ€“ South Med J, 2007

  5. ย Hypersensitivity Reaction of Mylotarg with Platelet Transfusion โ€“ Am J Health Syst Pharm, 2007

  6. ย Incidence of Hepatitis B Reactivation after Rituximab Therapy โ€“ Am J Hematol, 2009

  7. Outcomes After Auto-SCT in African Americans with Multiple Myeloma โ€“ Bone Marrow Transplant, 2009

  8. ย HER-2 Status May Change in Recurrent Breast Cancer โ€“ Cancer Research, 2009

  9. ย Compartment Syndrome as Presentation of Chronic Myelogenous Leukemia โ€“ J Gen Intern Med, 2010

  10. ย Use of Insulin and its Effect on Survival in NSCLC โ€“ J Clin Oncol, 2009

Conclusion:

Dr. Amr AlHanbali demonstrates a stellar blend of clinical expertise, research productivity, academic mentorship, and leadership in hematology and oncology. His research contributions have practical implications in areas such as multiple myeloma, leukemia, transplant immunology, and chemotherapy safety.

He is highly deserving of recognition and stands out as a top contender for a Best Researcher Award, particularly in the categories of clinical research excellence, translational hematology, and medical education integration with research.

Yanlan Wang | Cancer Cell Biology | Best Researcher Award

Dr. Yanlan Wang | Cancer Cell Biology | Best Researcher Award

Dr. Yanlan Wang, Stanford, United States

Dr. Yanlan Wang is a distinguished postdoctoral research fellow at Stanford Universityโ€™s Department of Pathology. She works in the esteemed Dr. Gerald Crabtreeโ€™s lab, where her research revolves around leveraging molecular glues to reprogram cancer drivers and trigger apoptosis. With a strong background in immuno-oncology, antibody engineering, and small molecule therapeutics, Dr. Wang has made significant contributions to targeted cancer therapies. Her interdisciplinary collaborations, notably with Dr. Nathanael Grayโ€™s group, have explored the role of transcription factor complex-inducing compounds (TCIPs) in MLL-rearranged leukemia. Dr. Wang brings a rich international research experience from China and the U.S., with a career spanning translational medicine, biotechnology innovation, and academic excellence. She is known for her rigorous approach to scientific inquiry, collaborative spirit, and prolific publication record. Her passion for understanding and overcoming the mechanisms of cancer resistance positions her as a future leader in oncology drug development and precision medicine.

Publication Profile:ย 

Scopus

โœ… Strengths for the Award:

  1. Outstanding Research Focus
    Dr. Wangโ€™s work on molecular glues and transcription factor modulators represents cutting-edge approaches in cancer therapy, especially in targeting previously undruggable pathways.

  2. High Impact Publications
    With multiple first-author and co-corresponding author papers (e.g., J Immunol Methods 2025, Leukemia & Lymphoma 2020, Clin Pharmacol Ther 2021), Dr. Wang has demonstrated a strong track record in both fundamental and translational cancer research.

  3. Innovation & Translational Impact
    Her efforts in bispecific antibody engineering, IL-15 therapeutics, and AKR1C3-targeted prodrugs show clear applications in oncology drug development, bridging the lab and clinic.

  4. Prestigious Collaborations
    Collaborating with renowned researchers such as Dr. Gerald Crabtree and Dr. Nathanael Gray at Stanford indicates high confidence and integration in world-class research circles.

  5. Recognition & Awards
    She has received the Coxe Fellowship at Stanford and multiple merit-based scholarships, highlighting academic excellence and innovation.

  6. Leadership and Multidisciplinary Skills
    Dr. Wang has led several projects, authored high-level papers, and mentored junior researchers, showcasing both technical and leadership capability.

๐Ÿ”„ Areas for Improvement:

  1. Greater International Presentation Exposure
    Although she has strong publication credentials, more visibility through international oral presentations, keynote addresses, or panel roles would amplify her leadership profile.

  2. Independent Grant Record
    While she is currently in a postdoctoral role, seeking independent funding (e.g., K99/R00, early-career PI grants) would position her more competitively for independent investigator status.

  3. Patent or Commercial Translation
    Given the translational nature of her work, pursuit of intellectual property filings or biotech partnerships would further highlight impact.

๐ŸŽ“ Education:

Dr. Yanlan Wang began her academic journey at Xiangya School of Medicine, Central South University, where she earned her MBBS (M.D. equivalent) in June 2012. She continued at The Second Xiangya Hospital for her clinical residency, completing her M.S. in June 2015. Her pursuit of scientific excellence led her to earn a doctorate (M.D. equivalent to PhD) from Sun Yat-sen University in June 2018, with a research focus on microbial immunology and tumor biology. This diverse educational background gave her a solid foundation in both clinical medicine and biomedical research, allowing her to bridge translational gaps in cancer research. Her early training emphasized immunotherapy, molecular biology, and oncology, all of which paved the way for her postdoctoral work in cutting-edge labs. Her education reflects a consistent upward trajectory, marked by prestigious institutions, interdisciplinary training, and a seamless integration of clinical and scientific disciplines.

๐Ÿ”ฌ Experience:

Dr. Yanlan Wang is currently a postdoctoral research fellow in Dr. Gerald Crabtreeโ€™s lab at Stanford University, where she focuses on manipulating cancer cell pathways using molecular glues. Her prior research in China included pivotal roles in biotechnology innovation, including bispecific antibody engineering, prodrug design, and immune-oncology drug development. She has also collaborated extensively with Dr. Nathanael Grayโ€™s lab at Stanford, exploring the therapeutic potential of TCIPs in leukemia. Dr. Wang’s hands-on experience includes multiplex screening platforms, flow cytometry, in vivo tumor models, and translational immunotherapy development. Over the years, she has taken leadership roles in preclinical projects, manuscript authorship, and international scientific presentations. Her diverse rolesโ€”from clinical residency to laboratory innovationโ€”reflect her capability to translate complex scientific findings into therapeutic strategies. Dr. Wang has also mentored junior researchers and worked across multiple disciplines, underscoring her adaptability, leadership potential, and deep commitment to cancer research.

๐Ÿ… Awards and Honors:

Dr. Yanlan Wangโ€™s excellence has been recognized through several prestigious awards. At Stanford, she received the Coxe Fellowship in 2021, honoring outstanding postdoctoral researchers. During her doctoral training, she earned the Special Award of Merit for the BJ-001 Project at BJ Bioscience Inc. in 2019 for her impactful translational research. Her academic merit was consistently acknowledged through the Bidi Scholarship (2016โ€“2017) and Daxiang Scholarship (2015โ€“2016) at Sun Yat-sen University. These honors underscore her commitment to scientific excellence, innovation, and translational impact in oncology and immunotherapy. Her ability to receive awards across both academic and industrial settings highlights her versatility and the real-world relevance of her work. These distinctions serve as a testament to her leadership in cancer drug development, collaborative effectiveness, and contribution to next-generation therapeutic discoveries.

๐Ÿ” Research Focus:

Dr. Yanlan Wang’s research lies at the intersection of cancer biology, molecular pharmacology, and immunotherapy. At Stanford, she investigates how molecular glues can be used to hijack cancer drivers and activate apoptosis, offering a novel route for targeted cancer therapies. Her work involves multiplex molecular glue screening, understanding protein degradation pathways, and designing synthetic lethality strategies. In collaboration with Dr. Nathanael Gray, she is also studying Transcription factor Complex-Inducing Compounds (TCIPs) for the treatment of MLL-rearranged leukemia, a particularly aggressive form of blood cancer. Prior to this, her research focused on bispecific antibodies, prodrugs, and IL-15 based immunotherapeutics, with a vision to decouple efficacy from toxicity. Through a blend of basic science and translational applications, she aims to rewire oncogenic signaling pathways and enhance anti-tumor immunity. Her research combines drug discovery, systems biology, and precision oncology, pushing the boundaries of targeted cancer treatment.

๐Ÿ“š Publications Top Notes:

  1. ๐Ÿ”ฌ Quantitative flow cytometry using quantitative streptavidin-protein G-biotin beads (qBeads) โ€“ J Immunol Methods, 2025

  2. ๐Ÿงฌ A Bivalent Molecular Glue Linking Lysine Acetyltransferases to Oncogene-directed Cell Death โ€“ Cell (revising)

  3. ๐Ÿ’‰ Enhance IL15 anti-tumor efficacy by inhibiting its negative feedback mechanism โ€“ (in preparation)

  4. โš›๏ธ Decouple the toxicity and efficacy of BJ-001, an integrin targeting IL-15 โ€“ AACR Abstract, 2019

  5. ๐Ÿ”„ Decoupling the toxicity and efficacy of immunotherapeutics โ€“ SITC Abstract, 2019

  6. ๐Ÿงช An AKR1C3-specific prodrug with potent anti-tumor activities against T-ALL โ€“ Leukemia & Lymphoma, 2020

  7. ๐Ÿงซ A novel AKR1C3 specific prodrug TH3424 with potent anti-tumor activity in liver cancer โ€“ Clin Pharmacol Ther, 2021

  8. ๐Ÿงฒ A GPC3-targeting Bispecific Antibody, GPC3-S-Fab, with Potent Cytotoxicity โ€“ J Vis Exp, 2018

  9. ๐Ÿง  Identification of anti-CD16a single domain antibodies and their application in bispecific antibodies โ€“ Cancer Biol Ther, 2020

  10. ๐Ÿงฟ Bp-Bs, a novel T-cell engaging bispecific antibody with biparatopic Her2 binding โ€“ Mol Ther Oncolytics, 2019

  11. ๐Ÿงฐ A novel multi-functional anti-CEA-IL15 molecule displays potent anti-tumor activities โ€“ Drug Des Devel Ther, 2018

  12. ๐Ÿง  A single domain based anti-Her2 antibody has potent anti-tumor activities โ€“ Transl Oncol, 2018

๐Ÿงพ Conclusion:

Dr. Yanlan Wang is highly deserving of the Best Researcher Award. Her contributions to cancer therapeutics through novel molecular approaches, her collaborations with globally renowned labs, and her publication record reflect a researcher of exceptional caliber and promise. With a deep understanding of tumor biology, a commitment to innovation, and a growing leadership presence in oncology research, she is not only suitable for the award but stands as a strong role model for future biomedical researchers.

Chenlong YANG | Cancer Cell Biology | Best Researcher Award

Prof. Chenlong YANG | Cancer Cell Biology | Best Researcher Award

Prof. Chenlong YANG, Peking University Third Hospital, China

Dr. Chenlong Yang, M.D., Ph.D., is an accomplished neurosurgeon and research associate professor at the Department of Neurosurgery, Peking University Third Hospital. With over 15 years of clinical and research experience, he specializes in neuro-oncology, spinal neurosurgery, and translational neuroscience. Dr. Yang earned his M.D. from Shandong University and his Ph.D. in Neurological Surgery from Capital Medical University. He has trained and worked in prestigious institutions including Beijing Tiantan Hospital and the State Key Laboratory of Vascular Homeostasis and Remodeling. He has contributed significantly to advancements in brain tumor diagnostics, neuroimmunology, and surgical innovations, with numerous high-impact publications. Recognized internationally, he frequently presents at top neurosurgical conferences such as EANS and the Japan-China Neurosurgery Alliance. His research bridges basic science and clinical neurosurgery, aiming to improve surgical precision and therapeutic outcomes. Dr. Yang is also known for his leadership in collaborative, multidisciplinary research teams.

Publication Profile:ย 

Google Scholar

โœ… Strengths for the Award:

  1. ๐Ÿ“š Robust Academic and Clinical Training

    • Earned an M.D. from Shandong University and a Ph.D. in Neurological Surgery from Capital Medical University.

    • Completed clinical training at Beijing Tiantan Hospital, a top-tier neurosurgical institution in China.

  2. ๐Ÿ”ฌ Multidisciplinary and Translational Research Excellence

    • His research spans neuro-oncology, neuroimmunology, spinal neurosurgery, and advanced neuroimaging.

    • Conducted preclinical work on Alzheimer’s disease models and neuroprotection, along with current research in immune checkpoint therapy and intraoperative imaging.

  3. ๐Ÿ“ˆ High-Impact Publications

    • Over 20 peer-reviewed publications in journals such as Scientific Reports, J Exp Clin Cancer Res, Neurosurgical Review, and Biophysical Journal.

    • His research on chordomas, gliomas, and spinal tumors has significantly contributed to the field.

  4. ๐ŸŒ International Recognition

    • Speaker at major international conferences like EANS 2025 and KSNS 2024.

    • Previously awarded a scholarship by the Turkish Neurosurgical Society.

  5. ๐Ÿค Leadership in Collaboration

    • Plays a key role at the Center for Precision Neurosurgery and Oncology and the State Key Laboratory of Vascular Homeostasis and Remodeling, fostering interdisciplinary collaborations across neurosurgery, imaging, and immunotherapy.

  6. ๐ŸŽฏ Focus on Precision and Innovation

    • Pioneering high-resolution MRI techniques, fluorescent intraoperative navigation, and predictive modeling for neurosurgical outcomes.

๐Ÿ”„ Areas for Improvement:

  1. ๐Ÿ“Š Independent Research Lead

    • While he has several corresponding author papers, increasing his share of first-author or sole-PI grants would further elevate his research identity.

  2. ๐ŸŒ Global Collaborations

    • Though he has spoken at international conferences, expanding collaborative projects with leading global neuroscience centers could amplify impact.

  3. ๐Ÿ’ก Technology Commercialization

    • Given his innovation in imaging and diagnostics, pursuing intellectual property rights or translational funding (e.g., for clinical tools or surgical systems) could be a valuable next step.

  4. ๐Ÿ“„ Diversification of Research Outputs

    • A few review articles and meta-analyses would strengthen his role as a thought leader and field synthesizer.

๐Ÿ“˜ Education:

Dr. Yang pursued his foundational medical education at Shandong University, earning an M.D. in Clinical Medicine (2006โ€“2011). This training provided a solid clinical base and early exposure to neurology and internal medicine. He then advanced to a doctoral program at Capital Medical University, Beijing (2011โ€“2017), earning his Ph.D. in Neurological Surgery. During his Ph.D., he received specialized training in neurosurgical techniques and engaged in cutting-edge research, particularly focusing on neuro-oncology and degenerative neural diseases. As part of his early research career, he also worked at the Institute of Neurobiology, Shandong University, investigating neuroprotective agents and Alzheimer’s disease models. Dr. Yangโ€™s academic journey is characterized by rigorous clinical training and scientific inquiry, equipping him with the knowledge and skills essential for bridging the gap between the lab bench and the operating room. His education laid a strong foundation for his future contributions to precision neurosurgery and translational neuroscience.

๐Ÿ’ผ Experience:

Dr. Yang has over a decade of diversified experience across top medical and research institutions. He currently serves as a Research Associate Professor and Attending Physician at the Department of Neurosurgery, Peking University Third Hospital (2020โ€“present), where he leads several clinical and translational research projects. Prior to this, he completed a postdoctoral fellowship (2017โ€“2020) in the Department of Orthopedics at the same hospital, emphasizing spinal and neuro-oncologic conditions. From 2011 to 2017, he worked as a resident in Neurosurgery at Beijing Tiantan Hospital, one of China’s premier neurosurgical centers, gaining extensive experience in surgical treatments and neurovascular procedures. His roles span clinical surgery, research coordination, and academic instruction. Additionally, he actively contributes to the Center for Precision Neurosurgery and Oncology and the State Key Laboratory of Vascular Homeostasis and Remodeling, leading initiatives to improve patient outcomes through interdisciplinary innovations in neurosurgical care.

๐Ÿง  Research Focus:

Dr. Chenlong Yangโ€™s research integrates neurosurgery, oncology, immunology, and biomedical engineering. His primary focus lies in neuro-oncology, with a strong emphasis on chordoma biology, glioma immunotherapy, and molecular diagnostics. He explores immune checkpoint therapies, tumor microenvironment modulation, and the development of predictive models for neurosurgical complications such as postoperative delirium. Dr. Yang is also deeply involved in technological innovation in neurosurgery, investigating intraoperative fluorescence imaging, high-resolution MRI, and minimally invasive spinal techniques. His work on spatial learning, Alzheimer’s models, and neuroprotection during his early career continues to inform his translational research. He collaborates across disciplines, from molecular biologists to radiologists, aiming to build precision-guided therapeutic frameworks. His research is extensively published in journals like Scientific Reports, J Exp Clin Cancer Res, and Frontiers in Neurology. Through this work, Dr. Yang seeks to advance the standard of care in neurosurgical oncology and promote patient-specific interventions.

๐Ÿ“š Publication Top Notes:

  1. ๐Ÿงฌ SMARCB1 orchestrates cellular plasticity and oncogenic pathways in typical and chondroid chordomas

  2. ๐Ÿ›ก๏ธ Cracking Chordoma’s Conundrum: Immune Checkpoints Provide a Potential Modality

  3. ๐ŸŒฑ From glioma gloom to immune bloom: unveiling novel immunotherapeutic paradigms โ€“ a review

  4. ๐Ÿ’ก Intraoperative fluorescence redefining neurosurgical precision

  5. ๐Ÿง  The evolution and integration of technology in spinal neurosurgery: A scoping review

  6. ๐Ÿ‘๏ธ Single-cell transcriptomic atlas of aging macaque ocular outflow tissues

  7. ๐Ÿงฎ Risk stratification and predictive modeling of postoperative delirium in chronic subdural hematoma

  8. ๐Ÿ“ถ Characteristic fingerprint spectrum of ฮฑ-synuclein mutants on terahertz time-domain spectroscopy

  9. ๐Ÿ’ Normative profile of retinal nerve fiber layer thickness in cynomolgus monkeys

  10. ๐ŸŒ€ Accurate diagnosis and treatment of sacral meningeal cysts using high-resolution MRI

  11. ๐Ÿงช Intraspinal hemangioblastomas: analysis of 92 cases in a single institution

๐Ÿ Conclusion:

Dr. Chenlong Yang exemplifies the ideal profile of a cutting-edge clinician-scientist, merging neurosurgical precision with immunological insight and technological innovation. His commitment to patient-centered research, consistent academic output, and recognition on international platforms underscores his eligibility for the Best Researcher Award. With continued growth in independent leadership and global research impact, Dr. Yang is not only a deserving candidate now but is poised to become a prominent global figure in neurosurgical research in the years to come.